PPC
BIO icon

Park Place Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Park Place Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20K Sell
68
-6
-8% -$1.7K ﹤0.01% 674
2026
Q1 		$20.6K Hold
74
– – ﹤0.01% 486
2025
Q4 		$22.4K Buy
74
+6
+9% +$1.87K ﹤0.01% 444
2025
Q3 		$19.1K Hold
68
– – ﹤0.01% 461
2025
Q2 		$16.9K Hold
68
– – ﹤0.01% 500
2025
Q1 		$16.6K Hold
68
– – ﹤0.01% 494
2024
Q4 		$22.3K Hold
68
– – 0.01% 464
2024
Q3 		$22.8K Buy
68
+2
+3% +$635 0.01% 490
2024
Q2 		$18K Sell
66
-34
-34% -$9.89K 0.01% 523
2024
Q1 		$34.6K Sell
100
-95
-49% -$31.2K 0.01% 458
2023
Q4 		$63K Sell
195
-291
-60% -$91.2K 0.03% 388
2023
Q3 		$174K Buy
486
+21
+5% +$8.1K 0.05% 250
2023
Q2 		$176K Buy
465
+46
+11% +$18.7K 0.05% 261
2023
Q1 		$201K Buy
419
+25
+6% +$11.7K 0.06% 245
2022
Q4 		$166K Buy
+394
New +$159K 0.05% 266

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Park Place Capital's BIO Position: Q2 2026 in Review

Park Place Capital reduced its Bio-Rad Laboratories Class A (BIO) stake by 8.1% in Q2 2026, selling an estimated $1.7K and leaving 68 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #674.

Park Place Capital first reported a position in BIO in Q4 2022 and has held it in 15 quarters since. The position peaked at $201K in Q1 2023. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Park Place Capital held 68 shares of Bio-Rad Laboratories Class A worth $20K as of Q2 2026.
  • Park Place Capital sold 6 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.7K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #674 holding.
  • Park Place Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and has held it in 15 quarters since.
  • Park Place Capital's Bio-Rad Laboratories Class A position peaked at $201K in Q1 2023.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.